NigerTuberculosis profile
Population  2016 21 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 4 (2.4–6.1) 20 (12–30)
Mortality (HIV+TB only) 0.39 (0.24–0.57) 1.9 (1.2–2.7)
Incidence  (includes HIV+TB) 19 (12–27) 93 (60–132)
Incidence (HIV+TB only) 0.95 (0.6–1.4) 4.6 (2.9–6.6)
Incidence (MDR/RR-TB)** 0.66 (0.14–1.2) 3.2 (0.67–5.7)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1 (0.63–1.4) 6.2 (3.8–8.7) 7.3 (4.4–10)
Males 1.2 (0.72–1.6) 11 (6.5–15) 12 (7.2–17)
Total 2.2 (1.3–3.1) 17 (10–24) 19 (12–27)
TB case notifications, 2016  
Total cases notified 10 165
Total new and relapse 9 921
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 74%
          - % pulmonary 87%
          - % bacteriologically confirmed among pulmonary 89%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 52% (36–80)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.24 (0.12–0.39)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 378 5%
          - on antiretroviral therapy 374 99%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  330
(92–570)
Estimated % of TB cases with MDR/RR-TB 2.6% (0.1–5.1) 18% (0.1–36)  
% notified tested for rifampicin resistance <1% 43% 287
MDR/RR-TB cases tested for resistance to second-line drugs   34
Laboratory-confirmed cases MDR/RR-TB: 49, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 46, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 80% 10 323
Previously treated cases, excluding relapse, registered in 2015 66% 243
HIV-positive TB cases registered in 2015 62% 428
MDR/RR-TB cases started on second-line treatment in 2014 78% 46
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment 12%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
20% (19–22)
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-17 Data: www.who.int/tb/data